1. Incidence and Outcome of Chronic Graft-versus-Host Disease Using National Institutes of Health Consensus Criteria 
Madan Jagasia, Jennifer Giglia, Wichai Chinratanalab, Sheri Dixon, Heidi Chen, Haydar Frangoul, Brian Engelhardt, Stacey Goodman, John Greer, Adetola Kassim, David Morgan, Katherine Ruffner, Friedrich Schuening 
Biology of Blood and Marrow Transplantation 
Volume 13, Issue 10, Pages (October 2007)
DOI: /j.bbmt
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
A, OS for the entire cohort: stratified by presence or absence of GVHD after day 100 from SCT. Patients with GVHD after day 100 had a superior survival compared with patients without GVHD (44% versus 60%, P = .026). Time is measured from day 100 until last follow-up. B, OS: stratified by GVHD subtype as proposed by NIH consensus criteria. Kaplan-Meier plot shows significant difference in survival of various GVHD subtypes (P = .0005). C, OS: classic cGVHD compared to other subtypes (persistent, recurrent, delayed aGVHD, and overlap GVHD). Kaplan-Meier shows superior survival of classic cGVHD compared to other subtypes (3-year OS 68% versus 46%, P = .033).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
A, OS: stratified by severity at onset of GVHD (classic and overlap only) after day 100. Kaplan-Meier shows no difference in survival (P = .94). B, OS: stratified by peak severity of GVHD (classic and overlap only) after day 100. Kaplan-Meier shows no difference in survival (P = .94).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions